Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
West Pharmaceutical Services, Inc. (WST) had Normalized Income after Taxes of $128.20M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$805.00M |
|
$132.10M |
|
$501.10M |
|
$303.90M |
|
$648.40M |
|
$156.60M |
|
$4.90M |
|
$161.50M |
|
$161.50M |
|
$128.20M |
|
$132.10M |
|
$132.10M |
|
|
Normalized Income after Taxes |
$128.20M |
$156.60M |
|
-- |
|
72.30M |
|
72.70M |
|
$1.83 |
|
$1.82 |
|
| Balance Sheet Financials | |
$1.98B |
|
$1.73B |
|
$2.29B |
|
$4.27B |
|
$654.90M |
|
$202.80M |
|
$439.10M |
|
$1.09B |
|
$3.18B |
|
$3.06B |
|
$3.18B |
|
72.00M |
|
| Cash Flow Statement Financials | |
$754.80M |
|
$-285.90M |
|
$-185.10M |
|
$484.60M |
|
$791.30M |
|
$306.70M |
|
$23.80M |
|
$-61.20M |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|